The World Health Organization (WHO) has recently released reliable data about the
global epidemiology of cancer. Overall, cancer is one of the most common
diseases, with as many as 14 million new cases each year and accounting for
over 8.8 million deaths around the globe. These notable figures are further
aggravated by future projection of incidence and prevalence, wherein the total
number of new cancer cases is predicted to increase by over 70% over the next 2
decades, paralleled by a similarly increasing number of deaths . Notably, the
total expenditure for cancer totaled approximates 125 billion US$ in 2010 in
the United States, and is projected to increase to over 150 billion US$ in 2020.
Lung cancer is the most frequent cause of death for cancer worldwide (1.69
million deaths), followed by hepatic malignancies (788,000 deaths), colorectal
(774,000 deaths), gastric (754,000 deaths) and breast (571,000 deaths) cancers .
Like many other human chronic conditions, cancer is a clearly preventable disease. Notably, the World Cancer Research Fund has recently estimated that over 32% of cancer deaths can be avoided by ceasing cigarette smoke, whereas approximately 20% of all cancers may be prevented by reducing overweight, enhancing physical activity, limiting alcohol consumption, improving the nutritional status , but also reducing environmental or occupation exposure to carcinogenic substances. Irrespective of the unquestionable role of prevention in limiting the dramatic epidemiological burden of cancer, screening and early diagnosis are the cornerstones for establishing a timely therapeutic management, which may contribute to save many lives worldwide.Regardless of the rapid development of modern medicine and biology, cancer takes millions of human lives. Someone,worldwide, dies from cancer every 30 seconds. Everyone has friends or relatives who have died from or have been diagnosed with cancer.The key to successful cancer treatment is early diagnosis.
If detected at the early stage, when there are no visible symptoms, cancer can be cured without any complex aggressive therapies.LUVEN ICO is ONGOING PROJECT in the REAL sector of economy that promotes a unique cancer diagnostic technology designed to save millions of lives.
Scientific foundation of the method
Any process in the body reflects in the cell, a structural unit of the body. Buccal cells (cells from the inside of the cheek) are the fastest to respond to any changes.We have established some regularities in the changes in electrical activity of buccal cells and their cytomorphological parameters in case of any changes in the life processes.
By examining various parameters of cells and their combinations, our system called The Luven Diagnostic allows, with a high degree of accuracy, to detect oncological diseases, localization of a diseased organ, tendency of progression of the disease and comorbidities.
A large number of studies ,conducted in cancer centers ,showed that The Luven methods’ accuracy is up to 96% for some types of cancer, which is a very high rate comparable to biopsy.
Diagnostic procedure
- A patient card should be filled out in the computer program;
- A buccal swab is carefully collected with a mouth spatula and placed under the microscope;
- The program records a video from the microscope and transfers it to the processing center;
- Within several minutes the program receives a printable report;
Based on
data processing results the report shows:
- Cancer lesions in the body, if any;
- Predisposition or liability to cancer;
- Comorbidities according to the international classification of diseases (ICD-10 and TNM);
Patents
We already have patents in Ukraine and Russia, also we've submitted an application to WIPO that secures our international reputation and allows us to obtain local patents in various counries.
The technology for diagnosing cancer is protected by the official publication of WIPO (World Intellectual Property Organization) - WO2016089336 The use of technology without author's permission is prohibited:
ICO
information
At the preICO stage - 3 000 000 tokens (1st day bonus – 30%, 1st week bonus
– 25%, 2nd week bonus – 20%, 3d week bonus – 15%)At the ICO stage - 27 000 000 (1st week – 10%, 1 to 1 onwards)
9,000,000 tokens will be kept by the founders and developers of Luven Diagnostic.
Bonuses will be also awarded for the investment volume
>= 5,000 ETH 5%
>= 3,000 ETH 4%
>= 1,000 ETH 3%
>= 100 ETH 2%
>= 3 ETH 1%
Token standard: ERC20.
Rate: 1$ = 1 LVN
Participation in ICO is possible both with Ethereum and Bitcoin.
preICO
Start: 12.12.2017 12:00 GMT
Completion: 29.12.2017 12:00 GMT
ICO
Start: 15.01.2018 12:00 GMT
Completion: 28.02.2018 12:00 GMT
If all the tokens are sold out at the PREICO stage, ICO will start earlier.
For more informatio please visit :
Website : https://luvenmed.io/
WhitePaper : https://luvenmed.io/whitepaper/whitepaper_en.pdf
Twitter : https://twitter.com/LuvenmedI
0x7bdf35C638AC00d1A21F9Df3A1e632B30Fa058aC
No comments:
Post a Comment